Abstract
The in vitro activity of Fleroxacin (Ro23-6240; AM 833), a new fluorinated 4-quinolone, was compared to that of ciprofloxacin, enoxacin and A-56620, against 747 isolates from cancer patients. Fleroxacin inhibited more than 90% of Enterobacteriacea isolates at a concentration of ≤ 0.25 μg/ml. It was also extremely active against Aeromonas hydrophila and Haemophilus influenzae isolates with MIC90 values of 0.12 and 0.06 μg/ml, respectively. The MIC90 for Acinetobacter spp. Was 1.0 μg/ml, for Pseudomonas aeruginosa and Pseudomonas fluorescens 4.0 μg/ml, and for other Pseudomonas spp., 8.0 μg/ml. Staphylococcus aureus isolates including methicillin-resistant strains were inhibited by ≤ 1.0 μg/ml. The MIC90 for three different species of coagulase-negative Staphylococci was 1.0 μg/ml. Streptococcal species required 8-16 μg/ml for inhibition. Fleroxacin was also active against group JK-diphtheroids and Bacillus cereus. The overall activity of fleroxacin was similar to that of enoxacin and less than that of A-56620 and ciprofloxacin.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 448-454 |
| Number of pages | 7 |
| Journal | Chemotherapy |
| Volume | 34 |
| Issue number | 6 |
| DOIs | |
| State | Published - 1988 |
Keywords
- 4-Quinolones
- Broad antimicrobial spectrum
- Fleroxacin
ASJC Scopus subject areas
- Oncology
- Pharmacology
- Drug Discovery
- Pharmacology (medical)
- Infectious Diseases
Fingerprint
Dive into the research topics of 'In vitro activity of fleroxacin (Ro23-6240), a new fluorinated 4-quinolone against isolates from cancer patients'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS